CN101402587A - Substituted acethydrazide derivatives, preparation method and application thereof - Google Patents

Substituted acethydrazide derivatives, preparation method and application thereof Download PDF

Info

Publication number
CN101402587A
CN101402587A CNA2008101804866A CN200810180486A CN101402587A CN 101402587 A CN101402587 A CN 101402587A CN A2008101804866 A CNA2008101804866 A CN A2008101804866A CN 200810180486 A CN200810180486 A CN 200810180486A CN 101402587 A CN101402587 A CN 101402587A
Authority
CN
China
Prior art keywords
methylamino
acethydrazide
benzyl
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2008101804866A
Other languages
Chinese (zh)
Other versions
CN101402587B (en
Inventor
李松
杨春玲
肖军海
王莉莉
钟武
郑志兵
谢云德
李行舟
赵国明
王晓奎
周辛波
刘洪英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Priority to CN2008101804866A priority Critical patent/CN101402587B/en
Publication of CN101402587A publication Critical patent/CN101402587A/en
Priority to PCT/CN2009/001311 priority patent/WO2010060277A1/en
Application granted granted Critical
Publication of CN101402587B publication Critical patent/CN101402587B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to an acethydrazide derivative having the function of inhibiting tumor cells and substituted by general formula I and a formula a-c compound as well as medicinal salt or a solvate, a preparation method for the compounds, a medicament composition containing the compounds, and application of the compounds for preparing medicament used for treating cancer.

Description

Substituted acethydrazide derivatives and its production and use
Technical field
The present invention relates to the novel substituted acethydrazide derivatives that can activate procaspase-3, the preparation method of these compounds comprise the pharmaceutical composition of above-claimed cpd, and described compound is used to prepare the purposes of the medicine for the treatment of cancer.
Technical background
Apoptosis claims that again (programmed cell death PCD) is a multicellular animals development and a homeostatic important and basic process in programmed cell death.1972, three scientists such as kerr proposed apoptotic notion first: apoptosis (apoptosis) but be the cell removal mechanisms at work of the many processes of a kind of participation organism, by the cell of the gene programming regulation and control process of initiatively committing suiside.A common feature of cancer is exactly the apoptotic signal of opposing nature, and this resistivity is with the rise of some the key protein factors in the apoptotic process or reduce relevantly, and wherein caspase-3 is exactly the execution albumen of apoptosis.
The topmost substrate of Caspase-3 is poly (ADP-ribose) polysaccharase PARP, and PARP repairs with DNA, the gene complete monitoring is relevant, is the startup enzyme of apoptosis program.Caspase-3 is synthesized with the zymogen forms of non-activity, and by a safety catch---the 3-aspartic acid is kept this dormant state.Safety catch is arranged in the collar of a flexibility of big small subunit junction, interacts by polyion, forms salt bridge, and IETD175 protects with the hydrolysis site.It is the pH value that depends in the born of the same parents that procaspase-3 energy auto-activation in the normal cell becomes caspase-3 [17], after cell was accepted apoptotic signal, the pH value in the born of the same parents can be reduced to 6.8 by original 7.4, has destroyed the formation of salt bridge, thereby has exposed the hydrolysis site, carries out auto-activation.So can find that in most tumour cell the procaspase-3 level is very high, cell can not start automatic apoptosis system, and sick cell is finally built up into tumour.If can help procaspase-3 to change into activated apoptosis enzyme caspase-3 by extraneous strength, cell death inducing just can reach the purpose for the treatment of cancer.Therefore, exploitation procaspase-3 activator has a good application prospect.
Summary of the invention
The objective of the invention is to seek and develop the micromolecular compound that can directly act on and activate procaspase-3, reach inducing apoptosis of tumour cell, be used for the treatment of cancer.The inventor has been found that the compound of structural formula a-c has the effect that suppresses tumour cell, and the inventor finds that also compound of Formula I has the effect that suppresses tumour cell, the present invention is based on above-mentioned discovery and is accomplished.
Summary of the invention:
First aspect present invention provides compound of Formula I,
Figure A20081018048600101
Wherein:
N is 1 or 2;
Ar 1Be aromatic carbocyclic or aromatic heterocycle, it is optional to be selected from following substituting group list-or many-replacement: halogen, itrile group, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, carboxyalkyl, alkoxyl group, carbalkoxy, alkoxycarbonyl alkyl, alkoxy aromatic yl, carboxamide, carboxamido alkyl, alkyl, cycloalkyl, alkylthio, alkyl sulphinyl, alkyl sulphonyl, sulfamyl, amidino groups, cyano group, amino, amido, alkylamino, dialkylamino, alkyl amino alkyl, allyl group, alkynyl;
Ar 2Be at the ortho position of its tie point quilt-OR 2Aromatic carbocyclic or aromatic heterocycle that group replaces, wherein said aromatic carbocyclic or aromatic heterocycle be optional to be selected from following substituting group list-or many-replacement: halogen, itrile group, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, carboxyalkyl, carbalkoxy, alkoxycarbonyl alkyl, carboxamide, carboxamido alkyl, alkyl, cycloalkyl, alkylthio, alkyl sulphinyl, alkyl sulphonyl, sulfamyl, amidino groups, cyano group, amino, amido, alkylamino, dialkylamino, alkyl amino alkyl, allyl group, alkynyl;
A is O or S;
R 2And R 3Be selected from hydrogen, C independently of one another 1-C 6Alkyl group;
And pharmacologically acceptable salt and solvate.
According to the compound of first aspect present invention, wherein said aromatic carbocyclic is selected from: benzene, naphthalene, anthracene, phenanthrene, indenes, fluorenes, acenaphthene.
According to the compound of first aspect present invention, wherein said aromatic heterocycle is selected from: pyridine, pyrroles, furans, thiophene, pyrazoles, imidazoles, thiazole, oxazole, isoxazole, indoles, cumarone, benzoglyoxaline, carbazole, pyridazine, pyrimidine, pyrazine, quinoline, isoquinoline 99.9, purine, thiodiphenylamine, phenoxazine.
According to first aspect present invention compound, it is selected from:
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-and N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(3-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(3-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(3-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(3-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(3-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(3-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(3-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(3-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(3-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(3-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-hydroxyl-1-Ben Yajiaji)-2-(N-(3-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(3-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
N, N '-two (4-(benzyloxy) benzyl)-N, N '-dimethyl-ethylenediamine;
(E)-N '-(3,5-di-t-butyl Ben Yajiaji)-2-(4-benzyl-3-ketone-piperazinyl) acethydrazide; With
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(4-benzyl-3-ketone-piperazinyl) acethydrazide,
And pharmacologically acceptable salt and solvate.
Second aspect present invention provides the compound of formula a, b or c,
Figure A20081018048600131
Figure A20081018048600141
And pharmacologically acceptable salt and solvate.
Third aspect present invention provides the preparation method of the described compound of first aspect present invention, and this method may further comprise the steps:
1) make N, N '-dimethyl-ethylenediamine or N, N '-dimethylated propyl diethylenetriamine with have an Ar 1The compound of group part (such as but not limited to: reaction benzyl chloride), obtain formula 1 compound,
[the Ar in its Chinese style 1 1With the definition of n with the described general formula I of claim 1, this formula 1 compound preference is as being expressed as the compound of formula 1 ': Wherein R group (down together) is optional suitable substituting group]
2) make formula 1 compound and halogenated acetic acids methyl esters or halo ethyl sulfonic acid methyl esters (such as but not limited to methyl chloroacetate or chloroethene methylmesylate) reaction, obtain formula 2 compounds,
[the Ar in its Chinese style 2 1, A and n definition with the described general formula I of claim 1, these formula 2 compound preferences are as being expressed as the compound of formula 2 ': 2 ']
3) make hydrazine hydrate or replace hydrazine accordingly and formula 2 compounds carry out hydrazinolysis reaction, obtain formula 3 compounds,
Figure A20081018048600151
[the Ar in its Chinese style 3 1, A and n definition with the described general formula I of claim 1, these formula 2 compound preferences are as being expressed as the compound of formula 3 ':
4) make formula 3 compounds and have Ar 2The compound of group part (such as but not limited to: corresponding bigcatkin willow aldehydes or aromatic ketone compounds) reaction, obtain compound of Formula I,
Figure A20081018048600153
[each substituent definition is with the described general formula I of claim 1 in the formula, and this formula I compound preference is as being expressed as the compound of formula I ':
Figure A20081018048600154
Fourth aspect present invention provides the preparation method of the described formula a compound of second aspect present invention, and this method may further comprise the steps:
1) makes 4-benzyloxy benzylalcohol and SOCl 2Reaction obtains formula 1a compound,
Figure A20081018048600155
2) make N, N '-dimethyl-ethylenediamine and the reaction of formula 1a compound obtain formula a compound,
Figure A20081018048600161
Fourth aspect present invention also provides the preparation method of described formula b of second aspect present invention and c compound, and this method may further comprise the steps:
1) make the reaction of quadrol and benzyl chloride obtain formula 1bc compound.
Figure A20081018048600162
2) make formula 1 compound and formaldehyde carry out condensation reaction, obtain formula 2bc compound,
3) make the reaction of formula 2 compounds and methyl chloroacetate, obtain formula 3bc compound,
Figure A20081018048600164
4) make hydrazine hydrate or replace hydrazine accordingly and in solvent, reflux, add formula 3bc compound and carry out the hydrazinolysis reaction, obtain formula 4bc compound,
Figure A20081018048600165
5) make formula 4 compounds and corresponding aldehydes or ketone compounds reaction, obtain the compound of formula b or c,
Figure A20081018048600171
Fifth aspect present invention provides a kind of medicinal compositions, and it comprises each compound of first aspect present invention and second aspect, or its pharmacologically acceptable salt or solvate, and at least a pharmaceutically acceptable carrier, thinner or vehicle.
Sixth aspect present invention provide each compound of first aspect present invention and second aspect in preparation as the purposes in the medicine of tumour cell inhibitor.
Seventh aspect present invention provides treatment or the prevention disease relevant with tumour or the method for illness, and this comprises each compound of the first aspect present invention of object treatment that these needs are arranged or prevention significant quantity and second aspect.
Detailed Description Of The Invention:
As be used for this paper, term " aromatic carbocyclic " has its general sense well known in the art, it forms the group part in compound of Formula I, and it generally includes but is not limited to: benzene, naphthalene, anthracene, phenanthrene, indenes, fluorenes, acenaphthene, it can be chosen wantonly and be replaced by single or repeatedly replace.
As be used for this paper, term " aromatic heterocycle " has its general sense well known in the art, it forms the group part in compound of Formula I, and it generally includes but is not limited to: pyridine, pyrroles, furans, thiophene, pyrazoles, imidazoles, thiazole, oxazole, isoxazole, indoles, cumarone, benzoglyoxaline, carbazole, pyridazine, pyrimidine, pyrazine, quinoline, isoquinoline 99.9, purine, thiodiphenylamine, phenoxazine, it can be chosen wantonly and be replaced by single or repeatedly replace.
As being used for this paper, term " alkyl group " has its general sense well known in the art, and generally includes straight line or ramose chain-like alkyl, for example methyl, ethyl, propyl group, sec.-propyl, normal-butyl, sec-butyl, the tertiary butyl etc.
As being used for this paper, the group of following term representative has general sense well known in the art: halogen, itrile group, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, carboxyalkyl, alkoxyl group, carbalkoxy, alkoxycarbonyl alkyl, alkoxy aromatic yl, carboxamide, carboxamido alkyl, alkyl, cycloalkyl, alkylthio, alkyl sulphinyl, alkyl sulphonyl, sulfamyl, amidino groups, cyano group, amino, amido, alkylamino, dialkylamino, alkyl amino alkyl, allyl group, alkynyl.
According to the present invention, above-mentioned compound of Formula I or its pharmacologically acceptable salt or solvate can prepare with following exemplary method, wherein used intermediate is exemplary, other feasible intermediate that is used for this reaction that the present invention does not enumerate also is fit to certainly, and this exemplary method may further comprise the steps:
1) with N, N '-dimethyl-ethylenediamine or N, N '-dimethylated propyl diethylenetriamine is dissolved in the tetrahydrofuran (THF), is heated to backflow, slowly drips benzyl chloride again, and wherein the mol ratio of benzyl chloride and amine is 1: 6.The adularescent precipitation generates gradually, uses the TLC monitoring reaction.After treating that benzyl chloride reacts completely, stop heating, the cooling back screws out solvent, uses the NaOH solution washing, CH 2Cl 2Extraction will guarantee pH 〉=12 in the extraction process.Merge organic layer, column chromatography for separation obtains formula 1 compound:
Preference such as compound:
Figure A20081018048600182
The same general formula I of the definition of each group wherein.
2) formula 1 compound, the NaHCO that step 1) are obtained 3Join in the acetone, reflux, drip methyl chloroacetate or chloroethene methylmesylate again.Reaction is used column chromatography purification after finishing, and obtains formula 2 compounds:
Figure A20081018048600183
Preference such as compound:
Figure A20081018048600184
The same general formula I of the definition of each group wherein.
3) with ethanol as solvent, add hydrazine hydrate or replace hydrazine accordingly, splash into formula 2 compounds that step 2 obtains after the backflow, the hydrazinolysis reaction takes place, production 3 compounds:
Figure A20081018048600191
Preference such as compound:
Figure A20081018048600192
The same general formula I of the definition of each group wherein.
4) with formula 3 compounds and corresponding bigcatkin willow aldehydes or aromatic ketone compounds reaction, obtain compound of Formula I:
Figure A20081018048600193
Preference such as compound:
Figure A20081018048600194
The same general formula I of the definition of each group wherein.
According to the present invention, said structure formula a or its pharmacologically acceptable salt or solvate can prepare with following exemplary method, and this exemplary method may further comprise the steps:
1) 4-benzyloxy benzylalcohol is dissolved among the THF, places dry three-necked bottle, the entire reaction device is a sealed state, is vented on the stink cupboard with direct-cooled pipe in addition, adds SOCl again 2Stirring at room when raw material point disappears, adds water and finishes reaction.Ethyl acetate extraction merges organic layer, dried overnight.Concentrate and obtain formula 1a compound.
Figure A20081018048600195
2) with N, N '-dimethyl-ethylenediamine is dissolved in the tetrahydrofuran (THF), is heated to backflow, drips 4-benzyloxy benzyl chloride again, wherein benzyl chloride and N, and the mol ratio of N '-dimethyl-ethylenediamine is 2: 1.The adularescent precipitation generates gradually, uses the TLC monitoring reaction.After treating that 4-benzyloxy benzyl chloride reacts completely, stop heating, the cooling back screws out solvent, uses the NaOH solution washing, CH 2Cl 2Extraction will guarantee pH 〉=12 in the extraction process.Merge organic layer, column chromatography for separation obtains formula a compound.
Figure A20081018048600201
According to the present invention, said structure formula b and c or its pharmacologically acceptable salt or solvate can prepare with following exemplary method, and this exemplary method may further comprise the steps:
1) quadrol is dissolved among the THF, after mixing, is heated to little boiling, slowly splash into benzyl chloride, use the TLC monitoring reaction.After treating that benzyl chloride reacts completely, stop heating, the cooling back screws out solvent, uses the NaOH solution washing, CH 2Cl 2Extraction will guarantee pH 〉=12 in the extraction process.Merge organic layer, column chromatography for separation obtains formula 1bc compound.
Figure A20081018048600202
2) formula 1 compound is dissolved in methyl alcohol,, obtains formula 2bc compound, can directly cast single step reaction with formaldehyde generation condensation reaction.
Figure A20081018048600203
3) with step 2) the formula 2bc compound, the NaHCO that obtain 3Join in the acetone, reflux, drip methyl chloroacetate again.Reaction is used column chromatography purification after finishing, and obtains formula 3bc compound.
4) with ethanol as solvent, add hydrazine hydrate or replace hydrazine accordingly, splash into the formula 3bc compound that step 3) obtains after the backflow, the hydrazinolysis reaction takes place, production 4bc compound.
Figure A20081018048600211
5), obtain the compound of structural formula b or c with formula 4bc compound and corresponding aldehydes or ketone compounds reaction.
Figure A20081018048600212
It will be appreciated by those skilled in the art that The compounds of this invention also can use with the form of its pharmacologically acceptable salt or solvate.Acceptable salt comprises the salt of the routine that is formed by pharmaceutically acceptable mineral acid or organic acid or mineral alkali or organic bases and the acid salt of quaternary ammonium on the physiology of the compound of compound of Formula I and structural formula a-c.The example more specifically of suitable hydrochlorate comprises hydrochloric acid, Hydrogen bromide, sulfuric acid, phosphoric acid, nitric acid, perchloric acid, fumaric acid, acetate, propionic acid, succsinic acid, oxyacetic acid, formic acid, lactic acid, toxilic acid, tartrate, citric acid, pounces on the salt of acid, propanedioic acid, hydroxymaleic acid, toluylic acid, L-glutamic acid, phenylformic acid, Whitfield's ointment, fumaric acid, toluenesulphonic acids, methylsulfonic acid, naphthalene-2-sulfonic acid, Phenylsulfonic acid, hydroxynaphthoic acid, hydroiodic acid HI, oxysuccinic acid, steroic, tannic acid etc.Other acid as oxalic acid, though itself be not pharmaceutically acceptable, can be used to prepare the salt as intermediate, to obtain The compounds of this invention and pharmacologically acceptable salt thereof.The example more specifically of suitable alkali salt comprises sodium, lithium, potassium, magnesium, aluminium, calcium, zinc, N, N '-dibenzyl-ethylenediamin, chloro PROCAINE HCL, PHARMA GRADE, choline, diethanolamine, quadrol, N-methylglucosamine and procaine salt.When after this relating to compound of the present invention, comprise compound and pharmacologically acceptable salt and the solvate of compound of Formula I and structural formula a-c.
The present invention also comprises the prodrug of The compounds of this invention, and this prodrug promptly carries out chemical conversion by metabolic process once administration, becomes afterwards to have active medicine.Usually, this class prodrug is the functional derivatives of The compounds of this invention, and it changes into required formula I compound and the compound of structural formula a-c in vivo easily.For example, at " Design Of Prodrugs ", H Bund Saard, Elsevier edits, and has described in 1985 and has selected and the ordinary method of the suitable prodrug derivant of preparation.
The present invention also comprises the active metabolite of The compounds of this invention.
Another aspect of the present invention relates to pharmaceutical composition, and it contains raceme or the optically active isomer and at least a pharmaceutically acceptable carrier of The compounds of this invention, and it can be used for interior therapeutic and has biocompatibility.Described pharmaceutical composition can be prepared into various forms according to different way of administration.The mentioned compound of the present invention also can be prepared to various pharmacologically acceptable salts.
Pharmaceutical composition of the present invention comprises the compound of Formula I of the present invention of effective dose and compound or pharmaceutically acceptable salt thereof or hydrate and one or more suitable pharmaceutically acceptable carrier of structural formula a-c.The pharmaceutical carrier here includes but not limited to: ion-exchanger, aluminum oxide, aluminum stearate, Yelkin TTS, serum protein such as human serum albumin, buffer substance such as phosphoric acid salt, glycerine, Sorbic Acid, potassium sorbate, the partial glycerol ester mixture of saturated vegetable fatty acid, water, salt or ionogen, as protamine sulfate, Sodium phosphate dibasic, potassium hydrogen phosphate, sodium-chlor, zinc salt, colloidal silica, Magnesium Trisilicate, polyvinylpyrrolidone, cellulosic material, polyoxyethylene glycol, Xylo-Mucine, polyacrylic ester, beeswax, lanolin.
The pharmaceutical composition of The compounds of this invention can be used with following any-mode: oral, spraying sucks, rectal application, nasal cavity applied medicine, the cheek medication, local application, non-enterally administer, as in subcutaneous, vein, intramuscular, intraperitoneal, the sheath, in the ventricle, in the breastbone and intracranial injection or input, or by the medication of a kind of outer planting reservoir.Wherein preferred oral, intraperitoneal or intravenous administration mode.
When medicine for oral use, The compounds of this invention can be made into oral acceptable dosage form arbitrarily, includes but not limited to tablet, capsule, the aqueous solution or aqeous suspension.Wherein, the carrier that tablet uses generally comprises lactose and W-Gum, also can add lubricant such as Magnesium Stearate in addition.The thinner that capsule preparations uses generally comprises lactose and dried corn starch.Aqueous suspension preparation then normally mixes use with activeconstituents with examples of suitable emulsifiers and suspension agent.If desired, also can add some sweeting agents, perfume compound or tinting material in the above oral preparations form.
When local medication, particularly treat local external application easy to reach and suffer from face or organ, during as eyes, skin or lower intestinal tract nervous system disease, can The compounds of this invention be made different local application's dosage forms, specify as follows according to different trouble faces or organ:
When the eye topical application, The compounds of this invention can be mixed with the dosage form of a kind of micronization suspension or solution, and the carrier that uses is the Sterile Saline of isoosmotic certain pH, wherein can add also not adding preservative agent such as zephiran chloride alkoxide.For eye usefulness, also compound can be made paste form such as vaseline paste.
When topical application, The compounds of this invention can be made into suitable ointment, lotion or creme dosage form, wherein activeconstituents is suspended or is dissolved in one or more carriers.The spendable carrier of ointment formulation includes but not limited to: mineral oil, Albolene, white vaseline, propylene glycol, polyoxyethylene, polyoxytrimethylene, emulsifying wax and water; The spendable carrier of lotion or creme includes but not limited to: mineral oil, and sorbitan monostearate, polysorbate60, the n-Hexadecane ester type waxes, cetene is fragrant and mellow, 2-Standamul G, benzyl alcohol and water.
The all right aseptic injection preparation form medication of The compounds of this invention comprises aseptic injection water or oil suspension or aseptic injectable solution.Wherein, spendable carrier and solvent comprise water, Ringer's solution and isotonic sodium chlorrde solution.In addition, the fixed oil of sterilization also can be used as solvent or suspension medium, as direactive glyceride or two glyceryl ester.
It may be noted that in addition, the using dosage of The compounds of this invention and using method depend on all multifactor, comprise activity intensity, Time of Administration, metabolic rate, the severity of illness and diagnosis and treatment doctor's the subjective judgement of patient's age, body weight, sex, natural health situation, nutritional status, compound.Preferred using dosage is between 0.01～100mg/kg body weight/day, and wherein optimal dosage is in the 5mg/kg-10mg/kg body weight/day.
Embodiment
The present invention further specifies with following intermediate and embodiment, and these intermediates and embodiment are not construed as limiting the invention.
Melting point compound is measured by YRT-3 type fusing point instrument, and temperature is not calibrated. 1H-NMR spectrum is measured by Bruker ARX 400 type nuclear magnetic resonance spectrometers.The FAB mass spectrum is measured by Zabspect high resolution magnetic mass spectrometer.
The preparation of intermediate
Intermediate 1
Be equipped with in the 250mL three-necked bottle of thermometer, constant pressure funnel, reflux condensation mode one, add THF 100mL, N, N '-dimethyl-ethylenediamine 16mL (0.6mol) after mixing, is heated to little boiling, begin 10g benzyl chloride (0.1mol) is slowly splashed into, the control rate of addition, the adularescent precipitation generates gradually, uses the TLC monitoring reaction.After treating that benzyl chloride reacts completely, stop heating, the cooling back screws out solvent, uses the NaOH solution washing, CH 2Cl 2Extraction will guarantee pH 〉=12 in the extraction process.Merge organic layer, column chromatography for separation obtains the weak yellow liquid of intermediate 1, yield 90%. 1H-NMR(400MHz，CDCl 3)δppm：7.31(1H，m)，7.30(2H，m)，7.30(2H，m)，3.49(2H，s)，2.67(2H，t，J＝5.60，6.16Hz)，2.53(2H，t，J＝6.16，5.60Hz)，2.40(3H，s)，2.18(3H，s)；MS[M] +＝179.5m/e。
Intermediate 2
Figure A20081018048600242
In the 100mL flask, add 3.56g intermediate 1 (0.02mol) and 2.1g NaHCO 3(0.025mol) join in the 40mL acetone, reflux, drip 2.367g methyl chloroacetate (0.022mol) again.After reaction finishes,, get the weak yellow liquid of intermediate 2, yield 85% with column chromatography purification (eluent system is an ethyl acetate/petroleum ether). 1H-NMR(400MHz，CDCl 3)δppm：7.31(1H，m)，7.27(2H，m)，7.30(2H，m)，3.69(3H，s)，3.51(2H，s)，3.32(2H，s)，2.68(2H，t，J＝5.60，6.16Hz)，2.54(2H，t，J＝6.16，5.60Hz)，2.36(3H，s)，2.22(3H，s)；MS[M] +＝250.2m/e。
Intermediate 3
Add the hydrazine hydrate (0.06mol) of 2.1g 85% in the 250mL three-necked bottle, the 50mL dehydrated alcohol is heated to backflow, slow then Dropwise 5 .0g intermediate 2 (0.02mol).After reaction finishes, reaction solution is concentrated rear pillar separate (eluent: CH 2Cl 2/ methyl alcohol/ammoniacal liquor system), get white solid product 4.35g, yield 86.7%.MS[M] +＝250.1m/e。
Intermediate 4
Figure A20081018048600252
With the 4 tert butylbenzyl chloride is raw material, and operation is with intermediate 1.Get the weak yellow liquid product.MS[M] +＝234.2m/e。
Intermediate 5
Figure A20081018048600253
With intermediate 4 is raw material, and operation is with intermediate 2.Get the weak yellow liquid product.MS[M] +＝306.2m/e。
Intermediate 6
Figure A20081018048600261
With intermediate 5 is raw material, and operation is with intermediate 3.Get the weak yellow liquid product.MS[M] +＝306.2m/e。
Intermediate 7
Figure A20081018048600262
To be raw material to the methoxyl group benzyl chloride, operation is with intermediate 1.Get the weak yellow liquid product.MS[M] +＝208.2m/e。
Intermediate 8
Figure A20081018048600263
With intermediate 7 is raw material, and operation is with intermediate 2.Get the weak yellow liquid product.MS[M] +＝280.1m/e。
Intermediate 9
Figure A20081018048600264
With intermediate 8 is raw material, and operation is with intermediate 3.Get the weak yellow liquid product.MS[M] +＝280.1m/e。
Intermediate 10
Figure A20081018048600265
The 4-benzyloxy benzylalcohol of 500mg is dissolved among the 6mL THF, places the dry three-necked bottle of 50mL, the entire reaction device is a sealed state, is vented on the stink cupboard with direct-cooled pipe in addition, adds 0.5mL SOCl again 2Stirring at room when raw material point disappears, adds water and finishes reaction.The 5mL*3 ethyl acetate extraction merges organic layer, uses anhydrous Na 2SO 4Dried overnight.Concentrate and obtain 450mg white solid product intermediate 10. 1H-NMR(400MHz，CDCl 3)δppm：7.38(H，m)，7.19(2H，m)，6.91(2H，m)，5.20(2H，s)，3.45(2H，s)；MS[M] +＝232.0m/e。
Intermediate 11
Figure A20081018048600271
With intermediate 10 is raw material, and operation is with intermediate 1.Get the weak yellow liquid product.MS[M] +＝284.2m/e。
Intermediate 12
Figure A20081018048600272
With intermediate 11 is raw material, and operation is with intermediate 2.Get the weak yellow liquid product.MS[M] +＝356.2m/e。
Intermediate 13
Figure A20081018048600273
With intermediate 12 is raw material, and operation is with intermediate 3.Get the yellow liquid product.MS[M] +＝356.2m/e。
Intermediate 14
Figure A20081018048600281
With benzyl chloride and N, N '-dimethylated propyl diethylenetriamine is a raw material, and operation is with intermediate 1.Get the weak yellow liquid product.MS[M] +＝192.1m/e。
Intermediate 15
Figure A20081018048600282
With intermediate 14 is raw material, and operation is with intermediate 2.Get the yellow liquid product.MS[M] +＝264.2m/e。
Intermediate 16
Figure A20081018048600283
With intermediate 15 is raw material, and operation is with intermediate 3.Get the yellow liquid product.MS[M] +＝264.2m/e。
Intermediate 17
With 4 tert butylbenzyl chloride and N, N '-dimethylated propyl diethylenetriamine is a raw material, and operation is with intermediate 1.Get the weak yellow liquid product.MS[M] +＝248.2m/e。
Intermediate 18
With intermediate 17 is raw material, and operation is with intermediate 2.Get the weak yellow liquid product.MS[M] +＝320.2m/e。
Intermediate 19
With intermediate 18 is raw material, and operation is with intermediate 3.Get the weak yellow liquid product.MS[M] +＝320.2m/e
Intermediate 20
With to methoxyl group benzyl chloride and N, N '-dimethylated propyl diethylenetriamine is a raw material, and operation is with intermediate 1.Get the weak yellow liquid product.MS[M] +＝208.2m/e。
Intermediate 21
Figure A20081018048600293
With intermediate 20 is raw material, and operation is with intermediate 2.Get the weak yellow liquid product.MS[M] +＝294.2m/e。
Intermediate 22
Figure A20081018048600294
With intermediate 21 is raw material, and operation is with intermediate 3.Get the weak yellow liquid product.MS[M] +＝294.2m/e。
Intermediate 23
Figure A20081018048600295
Be equipped with in the 250mL three-necked bottle of thermometer, constant pressure funnel, reflux condensation mode one, add THF 100mL, quadrol 32mL (0.6mol), after mixing, be heated to little boiling, begin 10g benzyl chloride (0.1mol) is slowly splashed into, the control rate of addition, it is muddy that reaction solution becomes gradually, uses the TLC monitoring reaction.After treating that benzyl chloride reacts completely, stop heating, the cooling back screws out solvent, uses the NaOH solution washing, CH 2Cl 2Extraction will guarantee pH 〉=12 in the extraction process.Merge organic layer, column chromatography for separation obtains weak yellow liquid.
Intermediate 24
Figure A20081018048600301
In the dry flask of 200mL, add 4.5g (0.03mol) intermediate 1,100mL methyl alcohol, stirring at room, adding specification again is the formaldehyde 2.5g (0.03mol) of 35-40%, still room temperature reaction is used the TLC monitoring reaction.Raw material reaction is complete, stopped reaction.Screw out solvent, obtain the 4.8g weak yellow liquid, yield almost 100% can directly be cast single step reaction. 1H-NMR(400MHz，CDCl 3)δppm：7.33(5H，m)，3.65(2H，d)，3.50(2H，d)，3.10(1H，t)，2.91(1H，t)，2.76(1H，t)，2.67(1H，t)，2.28(1H，s).
Intermediate 25
Figure A20081018048600302
In the 100mL three-necked bottle, add 3.24g intermediate 2 (0.02mol) and 2.1gNaHCO 3(0.025mol) join in the 40mL methyl alcohol, reflux, drip 2.36g methyl chloroacetate (0.022mol) again.After reaction finishes,, get weak yellow liquid, yield 34% with column chromatography purification (eluent system is an ethyl acetate/petroleum ether). 1H-NMR(400MHz，CDCl 3)δppm：7.32(5H，m)，3.74(3H，s)，3.72(2H，s)，3.54(2H，s)，3.45(2H，s)，2.99(2H，t，J＝6.44，13.2Hz)，2.54(2H，brm)；MS[M]+：234.14m/e。
Intermediate 26
Figure A20081018048600311
The hydrazine hydrate (6mmol) that in the 100mL three-necked bottle, adds 210mg 85%, the 10mL dehydrated alcohol, temperature of reaction is reduced to below-0 ℃, slow then Dropwise 5 00mg intermediate 3 (2mmol), rate of addition is slow as far as possible.After reaction finishes, reaction solution is concentrated rear pillar separate (eluent: CH 2Cl 2/ methyl alcohol/ammoniacal liquor system), obtain weak yellow liquid, yield is 27%.MS[M] +：263.1m/e。
Embodiment
Embodiment 1: (E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
500mg (0.2mmol) intermediate 3 is dissolved in the 10mL dehydrated alcohol, adds 3-allyl group salicylic aldehyde 380mg (0.24mmol), the 2 hours rear center bodies 3 of stirring that reflux react completely stopped reaction.The concentration of reaction solution rear pillar separates (eluent: methylene chloride/ammoniacal liquor system), get white solid, use ethyl alcohol recrystallization again, obtain white crystal. 1H-NMR(400MHz，CDCl 3)δppm：11.68(1H，s)，11.62(1H，s)，7.90(1H，s)，7.31(1H，m)，7.27(2H，m)，7.30(2H，m)，6.01(1H，m)，5.04(2H，m)，3.47(2H，m)，3.69(3H，s)，3.51(2H，s)，3.32(2H，s)，2.68(2H，t，J＝5.60，6.16Hz)，2.54(2H，t，J＝6.16，5.60Hz)，2.36(3H，s)，2.22(3H，s)；FAB-MS(m/z)：395.2[M+H] +。
Embodiment 2: (E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600321
With intermediate 3 and 3, the 5-di-tert-butyl salicylaldehyde is a raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.68(1H，s)，11.62(1H，s)，7.90(1H，s)，7.31(1H，m)，7.27(2H，m)，7.30(2H，m)，7.31(1H，m)，6.74(1H，m)，3.58(2H，s)，3.21(2H，s)，2.59(2H，t，J＝5.50，6.16Hz)，2.47(2H，t，J＝5.50，6.16Hz)，2.57(3H，s)，2.31(3H，s)，1.27(9H，s)，1.25(9H，s)；FAB-MS(m/z)：523.3[M+H] +。
Embodiment 3: (E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600322
With intermediate 3 and 4-N, N '-diethylamino salicylic aldehyde is a raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.30(1H，s)，11.24(1H，s)，7.38(1H，s)，7.37(1H，m)，7.33(4H，m)，6.57(1H，m)，6.12(1H，m)，6.19(1H，m)，3.34(4H，m)，3.35(2H，s)，3.23(2H，s)，2.59(2H，t，J＝5.50，6.16Hz)，2.49(2H，t，J＝5.50，6.16Hz)，2.34(3H，s)，2.19(3H，s)，1.16(6H，m)；FAB-MS(m/z)：426.3[M+H] +。
Embodiment 4: (E)-N '-(2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600323
With intermediate 3 and salicylic aldehyde is raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.68(1H，s)，11.23(1H，s)，7.64(1H，s)，7.38(5H，m)，7.24(1H，m)，6.95(1H，m)，6.80(1H，m)，6.72(1H，m)，3.59(2H，s)，3.27(2H，s)，2.62(2H，brm)，2.52(2H，brm)，2.39(3H，s)，2.20(3H，s)；MS(m/z)：354.0[M] +。
Embodiment 5: (E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600331
With intermediate 3 and 2-hydroxyl-1 naphthaldehyde is raw material, and operation is with embodiment 1.Get the faint yellow solid product. 1H-NMR(400MHz，CDCl 3)δppm：12.65(1H，s)，12.12(1H，s)，8.81(1H，s)，7.37(2H，m)，7.73(2H，m)，7.35(1H，m)，7.28(4H，m)，7.21(1H，m)，3.62(2H，s)，3.33(2H，s)，2.68(2H，t，J＝5.50，6.16Hz)，2.54(2H，t，J＝5.50，6.16Hz)，2.41(3H，s)，1.14(3H，s)；FAB-MS(m/z)：460.3[M+H] +。
Embodiment 6: (E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
With intermediate 6 and 3-allyl group salicylic aldehyde is raw material, and operation is with embodiment 1.Get white solid phase prod. 1H-NMR(400MHz，CDCl 3)δppm：11.84(1H，s)，11.50(1H，s)，7.56(1H，s)，7.39(2H，m)，7.33(2H，m)，7.12(1H，m)，6.71(1H，m)，6.49(1H，m)，6.01(1H，m)，5.04(2H，m)，3.47(2H，m)，3.54(2H，s)，3.28(2H，s)，2.64(2H，t，J＝5.50，6.16Hz)，2.52(2H，t，J＝5.50，6.16Hz)，2.41(3H，s)，2.16(3H，s)，1.31(9H，s)；FAB-MS(m/z)：451.3[M+H] +。
Embodiment 7: (E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600341
With intermediate 6 and 3, the 5-di-tert-butyl salicylaldehyde is a raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.68(1H，s)，11.62(1H，s)，7.90(1H，s)，7.38(1H，m)，7.36(1H，m)，7.33(2H，m)，7.31(1H，m)，6.74(1H，m)，3.58(2H，s)，3.21(2H，s)，2.59(2H，t，J＝5.50，6.16Hz)，2.47(2H，t，J＝5.50，6.16Hz)，2.57(3H，s)，2.31(3H，s)，1.43(9H，s)，1.27(9H，s)，1.25(9H，s)；FAB-MS(m/z)：523.3[M+H] +。
Embodiment 8: (E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
With intermediate 6 and 4-N, N '-diethylamino salicylic aldehyde is a raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.44(1H，s)，11.23(1H，s)，7.59(1H，s)，7.35(4H，m)，6.52(1H，m)，6.19(1H，m)，6.07(1H，m)，3.54(2H，s)，3.24(2H，s)，3.34(4H，m)，2.58(2H，t，J＝5.50，6.16Hz)，2.48(2H，t，J＝5.50，6.16Hz)，2.36(3H，s)，2.17(3H，s)，1.31(9H，s)，1.15(6H，m)；FAB-MS(m/z)：482.3[M+H] +。
Embodiment 9: (E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600351
With intermediate 9 and 3, the 5-di-tert-butyl salicylaldehyde is a raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.72(1H，s)，11.62(1H，s)，7.59(1H，s)，7.32(1H，m)，7.31(1H，m)，7.29(1H，m)，6.90(2H，m)，6.55(1H，m)，3.70(3H，s)3.51(2H，s)，3.27(2H，s)，2.64(2H，t，J＝5.50，6.16Hz)，2.51(2H，t，J＝5.50，6.16Hz)，2.42(3H，s)，2.18(3H，s)，1.42(9H，s)，1.29(9H，s)；FAB-MS(m/z)：497.3[M+H] +。
Embodiment 10: (E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
With intermediate 9 and 4-N, N '-diethylamino salicylic aldehyde is a raw material, and operation is with embodiment 1.Get the light yellow crystal product. 1H-NMR(400MHz，CDCl 3)δppm：11.34(1H，s)，11.25(1H，s)，7.59(1H，s)，7.29(2H，m)，7.26(1H，m)，6.89(1H，m)，6.59(1H，m)，6.19(1H，m)，6.14(1H，m)，3.51(2H，s)，3.22(2H，s)，3.37(3H，s)，3.34(4H，m)，2.58(2H，t，J＝5.50，6.16Hz)，2.48(2H，t，J＝5.50，6.16Hz)，2.35(3H，s)，2.18(3H，s)，1.15(6H，m)；FAB-MS(m/z)：456.2[M+H] +。
Embodiment 11: (E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600361
With intermediate 9 and 2-hydroxyl-1 naphthaldehyde is raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：12.73(1H，s)，12.17(1H，s)，8.69(1H，s)，7.35(4H，m)，7.73(1H，m)，7.21(1H，m)，7.18(1H，m)，7.14(1H，m)，6.83(2H，m)，3.61(3H，s)，3.56(2H，s)，3.33(2H，s)，2.69(2H，t，J＝5.50，6.16Hz)，2.53(2H，t，J＝5.50，6.16Hz)，2.47(3H，s)，2.24(3H，s)；FAB-MS(m/z)：460.3[M+H] +。
Embodiment 12: (E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600362
With intermediate 13 and 3, the 5-di-tert-butyl salicylaldehyde is a raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.72(1H，s)，11.61(1H，s)，7.65(1H，s)，7.34(4H，m)，7.31(3H，m)，6.97(1H，m)，6.95(2H，m)，6.60(1H，m)，4.95(2H，s)3.51(2H，s)，3.27(2H，s)，2.62(2H，t，J＝5.50，6.16Hz)，2.51(2H，t，J＝5.50，6.16Hz)，2.39(3H，s)，2.20(3H，s)，1.42(9H，s)，1.25(9H，s)；FAB-MS(m/z)：573.3[M+H] +。
Embodiment 13: (E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600371
With intermediate 13 and 3-allyl group salicylic aldehyde is raw material, and operation is with embodiment 1.Get the white crystal product. 1H-NMR(400MHz，CDCl 3)δppm：11.71(1H，s)，11.52(1H，s)，7.60(1H，s)，7.32(4H，m)，7.21(4H，m)，7.15(1H，m)，6.96(1H，m)，6.94(1H，m)，6.75(1H，m)，6.10(1H，m)，5.05(2H，m)，4.97(2H，s)，3.51(2H，s)，3.47(2H，m)，3.26(2H，s)，2.60(2H，t，J＝5.50，6.16Hz)，2.51(2H，t，J＝5.50，6.16Hz)，2.38(3H，s)，2.18(3H，s)；FAB-MS(m/z)：501.2[M+H] +。
Embodiment 14: (E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600372
With intermediate 13 and 2-hydroxyl-1-naphthalene first is raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：12.74(1H，s)，12.20(1H，s)，8.68(1H，s)，7.32(4H，m)，7.30(1H，m)，7.21(6H，m)，7.19(2H，m)，6.97(2H，m)，3.56(2H，s)，3.33(2H，s)，2.72(2H，t，J＝5.50，6.16Hz)，2.54(2H，t，J＝5.50，6.16Hz)，2.46(3H，s)，2.26(3H，s)；FAB-MS(m/z)：510.1[M+H] +。
Embodiment 15: N, N '-two (4-(benzyloxy) benzyl)-N, N '-dimethyl-ethylenediamine;
Figure A20081018048600373
Be equipped with in the 150mL=neck bottle of thermometer, constant pressure funnel, reflux condensation mode one, add THF 100mL, N, N '-dimethyl-ethylenediamine 2.4mL (0.02mol) after mixing, is heated to little boiling, begin 10g intermediate 10 (0.04mol) is slowly splashed into, the control rate of addition, the adularescent precipitation generates gradually, uses the TLC monitoring reaction.After treating that benzyl chloride reacts completely, stop heating, the cooling back screws out solvent, uses the NaOH solution washing, CH 2Cl 2Extraction will guarantee pH 〉=12 in the extraction process.Merge organic layer, crystallization obtains white crystal, yield 90%. 1H-NMR(400MHz，CDCl 3)δppm：7.37(10H，m)，7.20(4H，m)，6.91(4H，m)，5.04(4H，s)，3.44(4H，s)，2.53(4H，s)，2.19(6H，s)；FAB-MS(m/z)：481.1[M+H] +。
Embodiment 16: (E)-N '-(3,5-di-t-butyl-2-phenol methylene)-3-(N-(2-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600381
With intermediate 16 and 3, the 5-di-tert-butyl salicylaldehyde is a raw material, and operation is with embodiment 1.Get the white solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.41(1H，s)，10.29(1H，s)，8.22(1H，s)，7.35(2H，m)，7.32(2H，m)，7.30(1H，m)，7.24(1H，m)，6.92(1H，s)，3.57(2H，s)，3.21(2H，s)，2.56(2H，t，J＝6.72，6.76Hz)，2.56(2H，t，J＝6.72，6.76Hz)，2.33(3H，s)，2.27(3H，s)，1.74(2H，m)，1.43(9H，s)，1.29(9H，s)；MS(m/z)：480.3[M] +。
Embodiment 17: (E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-3-(N-(2-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600382
With intermediate 16 and 4-N, N '-diethylamino salicylic aldehyde is a raw material, and operation is with embodiment 1.Get the faint yellow solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.15(1H，s)，10.20(1H，s)，8.15(1H，s)，7.32(4H，m)，6.93(1H，d)，6.18(2H，m)，3.57(2H，br)，3.37(4H，J＝7.00，7.28，21.28Hz，dd)，3.18(2H，s)，2.54(2H，t，J＝6.72，6.76Hz)，2.51(2H，br)，2.32(3H，s)，2.27(3H，s)，1.73(2H，m)，1.18(6H，t，J＝7.04，7.00Hz)；FAB-MS(m/z)：440.1[M+H] +。
Embodiment 18: (E)-N '-(3-allyl group-2-phenol methylene)-3-(N-(2-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
With intermediate 16 and 3-allyl group salicylic aldehyde is raw material, and operation is with embodiment 1.Get the weak yellow liquid product. 1H-NMR(400MHz，CDCl 3)δppm：11.35(1H，s)，10.41(1H，s)，8.24(1H，s)，7.30(7H，m)，6.98(1H，m)，6.82(1H，m)，6.04(1H，m)，5.07(2H，m)，3.54(2H，br)，3.46(2H，m)，3.20(2H，s)，2.51(2H，m)，2.49(2H，brm)，2.32(3H，s)，2.26(3H，s)，1.73(2H，m)；FAB-MS(m/z)：409.1[M+H] +。
Embodiment 19: (E)-N '-(2-hydroxyl-1-naphthyl methylene)-3-(N-(2-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600392
With intermediate 22 and 3-isopropoxy propylamine is raw material, and operation is with embodiment 1.Get the faint yellow solid product. 1H-NMR(400MHz，CDCl 3)δppm：12.50(1H，s)，10.73(1H，s)，9.28(1H，s)，7.77(3H，m)，7.45(1H，m)，7.40(5H，m)，7.21(2H，m)，3.60(2H，s)，3.27(2H，s)，2.58(2H，t，J＝6.72，6.76Hz)，2.54(2H，br)，2.37(3H，s)，2.29(3H，s)，1.78(2H，m)；MS(m/z)：418.0[M] +。
Embodiment 20: (E)-N '-(3,5-di-t-butyl-2-phenol methylene)-3-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600401
With intermediate 19 and 3, the 5-di-tert-butyl salicylaldehyde is a raw material, and operation is with embodiment 1.Get the faint yellow solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.43(1H，s)，10.36(1H，s)，8.26(1H，s)，7.35(2H，m)，7.34(2H，m)，7.30(1H，m)，6.95(1H，s)，3.50(2H，s)，3.22(2H，s)，2.56(2H，t，J＝6.72，6.76Hz)，2.56(2H，t，J＝6.72，6.76Hz)，2.34(3H，s)，2.26(3H，s)，1.75(2H，br)，1.43(9H，s)，1.43(9H，s)，1.29(9H，s)；FAB-MS(m/z)：537.4[M+H] +。
Embodiment 21: (E)-N '-(3-allyl group-2-phenol methylene)-3-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600402
With intermediate 19 and 3-allyl group salicylic aldehyde is raw material, and operation is with embodiment 1.Get faint yellow oily product. 1H-NMR(400MHz，CDCl 3)δppm：11.43(1H，s)，8.29(1H，s)，7.33(2H，m)，7.27(2H，m)，7.14(1H，m)，6.97(1H，m)，6.81(1H，m)，6.02(1H，m)，5.06(2H，m)，3.58(2H，br)，3.45(2H，m)，3.27(2H，s)，2.56(4H，m)，2.34(3H，s)，2.31(3H，s)，1.78(2H，brm)，1.26(9H，s)；FAB-MS(m/z)：465.1[M+H] +。
Embodiment 22: (E)-N '-(2-hydroxyl-1-naphthyl methylene)-3-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600403
With intermediate 19 and 2-hydroxyl-1-naphthaldehyde is raw material, and operation is with embodiment 1.Get the faint yellow solid product. 1H-NMR(400MHz，CDCl 3)δppm：12.52(1H，s)，9.23(1H，s)，7.75(3H，m)，7.32(3H，m)，7.30(2H，m)，7.28(2H，m)，3.53(2H，s)，3.27(2H，s)，2.58(2H，t，J＝6.72，6.76Hz)，2.54(2H，br)，2.38(3H，s)，2.26(3H，s)，1.78(2H，m)，1.18(9H，s)；FAB-MS(m/z)：475.0[M+H] +。
Embodiment 23: (E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-3-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600411
With intermediate 19 and 4-N, N '-diethylamino salicylic aldehyde is a raw material, and operation is with embodiment 1.Getting faint yellow solid produces. 1H-NMR(400MHz，CDCl 3)δppm：11.14(1H，s)，10.20(1H，s)，8.11(1H，s)，7.30(2H，m)，7.24(2H，m)，6.88(1H，m)，6.19(2H，m)，3.49(2H，s)，3.34(4H，m)，3.17(2H，s)，2.53(2H，t，J＝6.72，6.76Hz)，2.46(2H，br)，2.33(3H，s)，2.22(3H，s)，1.75(2H，m)，1.27(9H，s)，1.17(6H，t，J＝7.04，7.00Hz)；FAB-MS(m/z)：496.2[M+H] +。
Embodiment 24: (E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-3-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600412
With intermediate 22 and 4-N, N '-diethylamino salicylic aldehyde is a raw material, and operation is with embodiment 1.Get the faint yellow solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.15(1H，s)，10.25(1H，s)，8.13(1H，s)，7.22(2H，m)，6.90(1H，d)，6.83(1H，s)，6.81(1H，s)，6.18(3H，m)，3.74(3H，s)，3.47(2H，s)，3.36(4H，J＝7.00，7.28，21.28Hz，dd)，3.17(2H，s)，2.53(2H，t，J＝6.72，6.76Hz)，2.46(2H，br)，2.32(3H，s)，2.23(3H，s)，1.72(2H，m)，1.18(6H，t，J＝7.04，7.00Hz)；FAB-MS(m/z)：470.1[M+H] +。
Embodiment 25: (E)-N '-(2-hydroxyl-1-naphthyl methylene)-3-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600421
With intermediate 22 and 2-hydroxyl-1-naphthaldehyde is raw material, and operation is with embodiment 1.Get the faint yellow solid product. 1H-NMR(400MHz，CDCl 3)δppm：12.48(1H，s)，9.25(1H，s)，7.78(3H，m)，7.45(1H，m)，7.33(1H，m)，7.22(3H，m)，6.80(1H，m)，6.77(1H，m)3.65(3H，s)，3.48(2H，s)，3.25(2H，s)，2.57(2H，t，J＝6.72，6.76Hz)，2.48(2H，brm)，2.37(3H，s)，2.25(3H，s)，1.78(2H，m)；FAB-MS(m/z)：449.0[M+H] +。
Embodiment 26: (E)-N '-(3,5-di-t-butyl-2-phenol methylene)-3-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600422
With intermediate 22 and 3, the 5-di-tert-butyl salicylaldehyde is a raw material, and operation is with embodiment 1.Get the faint yellow solid product. 1H-NMR(400MHz，CDCl 3)δppm：11.44(1H，s)，10.39(1H，s)，8.20(1H，s)，7.35(1H，m)，7.23(1H，br)，7.21(1H，br)，6.90(1H，br)，6.82(1H，br)，6.80(1H，br)，3.68(3H，s)，3.46(2H，s)，3.21(2H，s)，2.54(2H，t，J＝6.72，6.76Hz)，2.45(2H，brm)，2.33(3H，s)，2.23(3H，s)，1.73(2H，m)，1.43(9H，s)，1.25(9H，s)；FAB-MS(m/z)：511.1[M+H] +。
Embodiment 27: (E)-N '-(3-allyl group-2-phenol methylene)-3-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
Figure A20081018048600431
With intermediate 22 and 3-allyl group salicylic aldehyde is raw material, and operation is with embodiment 1.Get faint yellow oily product. 1H-NMR(400MHz，CDCl 3)δppm：11.37(1H，s)，11.50(1H，s)，8.21(1H，s)，7.21(3H，m)，6.95(1H，m)，6.80(3H，m)，6.03(1H，m)，5.07(2H，m)，3.69(3H，s)，3.45(4H，m)，3.20(3H，s)，2.53(2H，t)，2.46(2H，brm)，2.32(3H，s)，2.23(3H，s)，1.73(2H，m)；FAB-MS(m/z)：439.2[M+H] +。
Embodiment 28: (E)-N '-(2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
Figure A20081018048600432
With intermediate 6 and 2-hydroxy benzaldehyde is raw material, and operation is with embodiment 1.Get the faint yellow solid product. 1H-NMR(400MHz，CDCl 3)δppm：12.31(1H，s)，11.63(1H，s)，9.12(1H，s)，7.54(2H，m)，7.45(2H，m)，7.33(1H，m)，7.27(2H，m)，6.95(1H，brm)，6.88(1H，brm)，4.30(2H，s)，3.31(2H，s)，3.07(2H，m)，2.79(2H，m)，2.87(3H，s)，2.28(3H，s)，1.28(9H，s)；MS(m/z)：410.0[M] +。
Embodiment 29: (E)-N '-(3,5-di-t-butyl Ben Yajiaji)-2-(4-benzyl-3-ketone-piperazinyl) acethydrazide
Figure A20081018048600433
147mg (0.5mmol) intermediate 26 is dissolved in the 10mL dehydrated alcohol, adds 3,5-di-tert-butyl salicylaldehyde 176mg (0.75mmol) refluxes and stirs, and intermediate 26 reacts completely, stopped reaction.The evaporating column chromatographic separation (eluent: methylene chloride/ammoniacal liquor system), gray solid, use ethyl alcohol recrystallization, obtain white crystal 140, yield is 58%, m.p.229～232 ℃. 1H-NMR(400MHz，CDCl 3)δppm：12.10(1H，s)，11.62(1H，s)，8.45(1H，s)，7.35(2H，m)，7.28(3H，m)，7.17(2H，m)，4.53(2H，s)，3.28(4H，s)，3.26(2H，m)，2.78(2H，t，J＝4.76，9.08Hz)，1.38(3H，s)，1.26(3H，s)；FAB-MS(m/z)：478.1[M+H] +。
Embodiment 30: (E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(4-benzyl-3-ketone-piperazinyl) acethydrazide
With intermediate 26 and 2 hydroxy naphthalene formaldehyde is raw material, and operation is with embodiment 31.Obtain yellow crystals, yield is 75%, m.p.186～188 ℃. 1H-NMR(400MHz，CDCl 3)δppm：12.67(1H，s)，11.62(1H，s)，9.41(1H，s)，8.19(1H，m)，7.90(2H，m)，7.48(1H，m)，7.36(4H，m)，7.29(2H，m)，7.19(2H，m)，4.55(2H，s)，3.32(2H，s)，3.29(2H，m)，2.82(2H，m)；MS(m/z)：416.0[M+H] +。
The active available mtt assay that the present invention relates to the antitumor cell of compound detects, and is specific as follows:
Embodiment 31: the activity rating of compound antitumor cell of the present invention
1, get the HL60 cell of exponential phase of growth, counting, inoculating cell is in 96 well culture plates, and inoculum density is 3 * 10 3Individual/hole, 100 μ L/ holes, parallel 3 holes of each compound concentration.
2, behind the cell cultures 24h, give certain density compound, the compound effects time is 72h.
3, behind the 72h, every hole adds tetrazolium bromide (MTT) solution of 5mg/mL, and 37 ℃ are continued to hatch 4h.
4, every then hole adds the SDS of 100 μ L 10%, hatches 24h for 37 ℃, and the bluish voilet crystallisate is fully dissolved.
5, select the wavelength of 570nm, on enzyme-linked immunosorbent assay instrument, measure each hole absorbance value, calculate and suppress percentage.Try to achieve the IC50 value of each compound according to suppressing percentage.
Inhibition activity (the IC of part embodiment compound 50)
Embodiment number IC 50(μM) Embodiment number IC 50(μM)
3 0.27 17 0.64
5 0.28 19 0.84
6 0.73 20 1.23
7 0.82 21 0.99
8 0.25 22 0.28
9 0.91 23 0.26
10 0.30 24 0.46
11 0.56 25 0.71
12 1.11 26 0.54
13 0.73 28 0.38
14 0.26 29 2.08
15 1.66 30 1.09
16 0.85

Claims (11)

1, compound of Formula I,
Figure A2008101804860002C1
Wherein:
N is 1 or 2;
Ar 1Be aromatic carbocyclic or aromatic heterocycle, it is optional to be selected from following substituting group list-or many-replacement: halogen, itrile group, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, carboxyalkyl, alkoxyl group, carbalkoxy, alkoxycarbonyl alkyl, alkoxy aromatic yl, carboxamide, carboxamido alkyl, alkyl, cycloalkyl, alkylthio, alkyl sulphinyl, alkyl sulphonyl, sulfamyl, amidino groups, cyano group, amino, amido, alkylamino, dialkylamino, alkyl amino alkyl, allyl group, alkynyl;
Ar 2Be at the ortho position of its tie point quilt-OR 2Aromatic carbocyclic or aromatic heterocycle that group replaces, wherein said aromatic carbocyclic or aromatic heterocycle be optional to be selected from following substituting group list-or many-replacement: halogen, itrile group, trifluoromethyl, trifluoromethoxy, hydroxyl, nitro, carboxyalkyl, carbalkoxy, alkoxycarbonyl alkyl, carboxamide, carboxamido alkyl, alkyl, cycloalkyl, alkylthio, alkyl sulphinyl, alkyl sulphonyl, sulfamyl, amidino groups, cyano group, amino, amido, alkylamino, dialkylamino, alkyl amino alkyl, allyl group, alkynyl;
A is O or S;
R 2And R 3Be selected from hydrogen, C independently of one another 1-C 6Alkyl group;
And pharmacologically acceptable salt and solvate.
2, the compound of claim 1, wherein said aromatic carbocyclic is selected from: benzene, naphthalene, anthracene, phenanthrene, indenes, fluorenes, acenaphthene.
3, the compound of claim 1, wherein said aromatic heterocycle is selected from: pyridine, pyrroles, furans, thiophene, pyrazoles, imidazoles, thiazole, oxazole, isoxazole, indoles, cumarone, benzoglyoxaline, carbazole, pyridazine, pyrimidine, pyrazine, quinoline, isoquinoline 99.9, purine, thiodiphenylamine, phenoxazine.
4, each compound of claim 1 to 3, it is selected from:
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-and N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(2-(N-(4-methoxy-benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(2-(N-(4-benzyloxy benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(3-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(3-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(3-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(3-(N-benzyl-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(3-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(3-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-phenol methylene)-2-(N-(3-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(3-(N-(4-tertiary butyl benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3-allyl group-2-phenol methylene)-2-(N-(3-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3,5-di-t-butyl-2-phenol methylene)-2-(N-(3-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(4-N, N '-diethylamino-2-hydroxyl-1-Ben Yajiaji)-2-(N-(3-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(N-(3-(N-(4-methoxy-benzyl)-N-methylamino) propyl group) N-methylamino) acethydrazide;
(E)-N '-(3-phenol methylene)-2-(N-(2-(N-benzyl-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(2-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
(E)-N '-(3-phenol methylene)-2-(N-(2-(N-(4-tertiary butyl benzyl)-N-methylamino) ethyl) N-methylamino) acethydrazide;
N, N '-two (4-(benzyloxy) benzyl)-N, N '-dimethyl-ethylenediamine;
(E)-N '-(3,5-di-t-butyl Ben Yajiaji)-2-(4-benzyl-3-ketone-piperazinyl) acethydrazide; With
(E)-N '-(2-hydroxyl-1-naphthyl methylene)-2-(4-benzyl-3-ketone-piperazinyl) acethydrazide,
And pharmacologically acceptable salt and solvate.
5, the compound of formula a, b or c,
Figure A2008101804860005C1
And pharmacologically acceptable salt and solvate.
6, the preparation method of each described compound of claim 1 to 4, this method may further comprise the steps:
1) make N, N '-dimethyl-ethylenediamine or N, N '-dimethylated propyl diethylenetriamine with have an Ar 1The compound reaction of group part obtains formula 1 compound,
[the Ar in its Chinese style 1 1With the definition of n with the described general formula I of claim 1]
2) make the reaction of formula 1 compound and halogenated acetic acids methyl esters or halo ethyl sulfonic acid methyl esters, obtain formula 2 compounds,
Figure A2008101804860006C2
[the Ar in its Chinese style 2 1, A and n definition with the described general formula I of claim 1]
3) make hydrazine hydrate or replace hydrazine accordingly and formula 2 compounds carry out hydrazinolysis reaction, obtain formula 3 compounds,
[the Ar in its Chinese style 3 1, A and n definition with the described general formula I of claim 1]
4) make formula 3 compounds and have Ar 2The compound reaction of group part obtains compound of Formula I,
Figure A2008101804860006C4
[each substituent definition is with the described general formula I of claim 1 in the formula].
7, the preparation method of the described formula a compound of claim 5, this method may further comprise the steps:
1) makes 4-benzyloxy benzylalcohol and SOCl 2Reaction obtains formula 1a compound,
Figure A2008101804860007C1
2) make N, N '-dimethyl-ethylenediamine and the reaction of formula 1a compound obtain formula a compound,
Figure A2008101804860007C2
8, the preparation method of described formula b of claim 5 and c compound, this method may further comprise the steps:
1) make the reaction of quadrol and benzyl chloride obtain formula 1bc compound.
Figure A2008101804860007C3
2) make formula 1 compound and formaldehyde carry out condensation reaction, obtain formula 2bc compound,
Figure A2008101804860007C4
3) make the reaction of formula 2 compounds and methyl chloroacetate, obtain formula 3bc compound,
Figure A2008101804860007C5
4) make hydrazine hydrate or replace hydrazine accordingly and in solvent, reflux, add formula 3bc compound and carry out the hydrazinolysis reaction, obtain formula 4bc compound,
Figure A2008101804860008C1
5) make formula 4 compounds and corresponding aldehydes or ketone compounds reaction, obtain the compound of formula b or c,
Figure A2008101804860008C2
9, a kind of medicinal compositions, it comprises each compound of claim 1 to 5, or its pharmacologically acceptable salt or solvate, and at least a pharmaceutically acceptable carrier, thinner or vehicle.
10, claim 1 to 5 each compound the preparation as the purposes in the medicine of tumour cell inhibitor.
11, the method for disease that treatment or prevention are relevant with tumour or illness, this comprises each the compound of claim 1 to 5 of object treatment that these needs are arranged or prevention significant quantity.
CN2008101804866A 2008-11-28 2008-11-28 Substituted acethydrazide derivatives, preparation method and application thereof Expired - Fee Related CN101402587B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2008101804866A CN101402587B (en) 2008-11-28 2008-11-28 Substituted acethydrazide derivatives, preparation method and application thereof
PCT/CN2009/001311 WO2010060277A1 (en) 2008-11-28 2009-11-24 Substituted acetyl hydrazide derivatives, their preparation and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008101804866A CN101402587B (en) 2008-11-28 2008-11-28 Substituted acethydrazide derivatives, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN101402587A true CN101402587A (en) 2009-04-08
CN101402587B CN101402587B (en) 2012-04-11

Family

ID=40536770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008101804866A Expired - Fee Related CN101402587B (en) 2008-11-28 2008-11-28 Substituted acethydrazide derivatives, preparation method and application thereof

Country Status (2)

Country Link
CN (1) CN101402587B (en)
WO (1) WO2010060277A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060277A1 (en) * 2008-11-28 2010-06-03 中国人民解放军军事医学科学院毒物药物研究所 Substituted acetyl hydrazide derivatives, their preparation and uses thereof
CN105218399A (en) * 2014-05-30 2016-01-06 中国人民解放军军事医学科学院毒物药物研究所 A kind of substituted acethydrazide derivatives, Preparation Method And The Use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239526A (en) * 1979-09-04 1980-12-16 W. R. Grace & Co. Substituted ureas as sugarcane ripeners
AU694495B2 (en) * 1994-03-28 1998-07-23 Ciba-Geigy Japan Limited Antagonists of endothelin receptors
DE10346913A1 (en) * 2003-10-09 2005-05-04 Merck Patent Gmbh acylhydrazone
CN101402587B (en) * 2008-11-28 2012-04-11 中国人民解放军军事医学科学院毒物药物研究所 Substituted acethydrazide derivatives, preparation method and application thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010060277A1 (en) * 2008-11-28 2010-06-03 中国人民解放军军事医学科学院毒物药物研究所 Substituted acetyl hydrazide derivatives, their preparation and uses thereof
CN105218399A (en) * 2014-05-30 2016-01-06 中国人民解放军军事医学科学院毒物药物研究所 A kind of substituted acethydrazide derivatives, Preparation Method And The Use
US10196346B2 (en) 2014-05-30 2019-02-05 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Substituted acethydrazide derivative, preparation method and use thereof

Also Published As

Publication number Publication date
CN101402587B (en) 2012-04-11
WO2010060277A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
CA2676984C (en) Compounds for the prevention and treatment of cardiovascular diseases
JP5758395B2 (en) Sepiapterin reductase inhibitors for the treatment of pain
CN101007798B (en) Benzodioxole derivatives and their preparation method and medicinal uses
CN101007804B (en) 1,3-benzodioxole-2,2-dicarboxylic acid derivatives and their preparation method and medicinal uses
JP4505753B2 (en) Lactam compounds and their pharmaceutical use
KR101266587B1 (en) Tissue factor production inhibitor
CN104718200B (en) Thiophene derivant for treating diabetes
WO2007081978A2 (en) Modulators of hepatocyte growth factor / c-met activity
JP2010505938A (en) Heterocyclic compounds useful as anabolic agents for livestock animals
CN102007104B (en) The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof
CN102050793A (en) 4(3H) quinazolinone derivatives with antitumor activity
CN101928254A (en) Benzotriazole derivatives and preparation method and use thereof
CN111518031A (en) Hydroxamic acid-containing compound and preparation method and application thereof
CN105693665B (en) Hydrazone derivative of the ring containing benzofuran and preparation method thereof and medical usage
JP2004523576A (en) Substituted benzopyranones as telomerase inhibitors
CN101402587B (en) Substituted acethydrazide derivatives, preparation method and application thereof
CN110156769A (en) Compound and its preparation method and application with xanthine oxidase inhibitory activity
CN110467616B (en) Preparation and application of triazolopyrazine compound containing heteroaryl substituted pyridazinone structure
CN105541859B (en) Dihydrofuran and chromanone derivatives and preparation method thereof and medical usage
CN107922375A (en) Target the antitumoral compounds and its application method of IDH2 mutation
SK2722002A3 (en) Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia
CN106349257B (en) The double B-carboline alkaloid compounds and its pharmaceutical applications that 3 piperazine bridgings connect
CN111393421A (en) Butenolide derivative and preparation method and application thereof
CN102382076B (en) Arone and aryl amide compound and preparation method thereof and medicinal usage
CN101321738A (en) Spirocyclic derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120411

Termination date: 20191128